{"id":1019849,"date":"2026-11-11T01:03:08","date_gmt":"2026-11-11T06:03:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/"},"modified":"2026-11-11T01:03:08","modified_gmt":"2026-11-11T06:03:08","slug":"innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/","title":{"rendered":"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth30 { width: 30% }\n.bwwidth70 { width: 70% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026<\/b><\/p>\n<p>MARSEILLE, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:<\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET \/ 4:00 PM GMT, in London, at the IET London, Savoy Place.<\/p>\n<p>\nProfessor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (ENA) Symposium.<\/p>\n<p>\nThe event will include a review of the Phase 1 study&#8217;s safety, pharmacokinetic and antitumor activity findings, along with a discussion of the current treatment landscape and unmet medical need in urothelial cancer. Professor Loriot will provide his clinical perspective, while Innate management will discuss the scientific rationale for IPH4502 and next steps in its clinical development.<\/p>\n<p>\nA live question-and-answer session will follow the formal presentations.<\/p>\n<p><b>Event details<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEvent: <i>IPH4502 Phase 1 clinical data and development outlook<\/i><\/li>\n<li>\nDate and time: November 18, 2026 at 11:00 a.m. ET \/ 4:00 p.m. GMT<\/p>\n<\/li>\n<li>\nLocation: IET London, Savoy Place, 2 Savoy Place, London WC2R 0BL, United Kingdom<\/p>\n<\/li>\n<li>\nTo register for in person participation or virtual access, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flifescievents.com%2Fevent%2Finz37gy%2F&amp;esheet=54639283&amp;newsitemid=20261110192535&amp;lan=en-US&amp;anchor=click+here.&amp;index=1&amp;md5=3a1917ed12c380f78abca59fbbddabc0\"><b>click here.<\/b><\/a><\/li>\n<\/ul>\n<p>\nA replay will be available in the investors section of Innate Pharma website after the event.<\/p>\n<p><b>About Professor Yohann Loriot, M.D., Ph.D.<\/b><\/p>\n<p>\nProfessor Yohann Loriot is a medical oncologist and Professor of Medicine at Gustave Roussy, specializing in genitourinary cancers, with a particular focus on bladder cancer. He serves as Deputy Head of the Department of Therapeutic Innovation and Early Drug Development (DITEP) and coordinates the UNLOCK program, dedicated to understanding mechanisms of sensitivity and resistance to innovative cancer therapies.<\/p>\n<p>\nHe holds both a Medical Degree and a PhD in Anticancer Pharmacology and teaches at Paris-Saclay University. His research focuses on the development of novel therapeutic strategies and the identification of mechanisms of treatment resistance in solid tumors, particularly urothelial and prostate cancers.<\/p>\n<p>\nProfessor Loriot has authored more than 300 peer-reviewed scientific publications and is an active member of several leading international scientific societies, including ESMO, ASCO and AACR. He also leads the EORTC Urological Tumours Group and contributes to the development of European clinical guidelines in bladder cancer.<\/p>\n<p>\nScientific expert disclosure<\/p>\n<p>\nProfessor Yohann Loriot will participate as guest speaker and Gustave Roussy will receive compensation for his participation in the event, which doesn\u2019t constitute an endorsement of the investigational product or a recommendation for its use.<\/p>\n<p><b>About IPH4502<\/b><\/p>\n<p>\nIPH4502 is Innate Pharma&#8217;s proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance, and without the need for CYP2D6 genotyping. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). In preclinical studies, IPH4502 demonstrated anti-tumor activity in EV-resistant tumor models and in tumors with low and heterogeneous Nectin-4 expression, supporting its potential applicability across solid tumor types beyond urothelial carcinoma (UC). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study<b> (<\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06781983&amp;esheet=54639283&amp;newsitemid=20261110192535&amp;lan=en-US&amp;anchor=NCT06781983&amp;index=2&amp;md5=5b73446f0c5b3b15ad937c1f3d09a95a\"><b>NCT06781983<\/b><\/a><b>) <\/b>in patients with advanced solid tumors known to express Nectin-4.<\/p>\n<p>\nIPH4502 is currently under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established for any commercial use. The product is not available for commercial distribution.<\/p>\n<p><b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n<p>\nInnate Pharma is advancing a portfolio of differentiated potential first- and\/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for cutaneous T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).<\/p>\n<p>\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n<p>\nHeadquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54639283&amp;newsitemid=20261110192535&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=90ff1dc526724ff3467b3c21d6cee0e1\">www.innate-pharma.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54639283&amp;newsitemid=20261110192535&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=25bd8890fbf26ba0fb6124f78a0b5332\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FInnatePharma&amp;esheet=54639283&amp;newsitemid=20261110192535&amp;lan=en-US&amp;anchor=X&amp;index=5&amp;md5=9ee03a25d549540034cc0eec93deb7c5\">X<\/a>.<\/p>\n<p><b>Information about Innate Pharma shares<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth30\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\"><b>ISIN code<br \/>\n<\/b><br \/><b>Ticker code<br \/>\n<\/b><br \/><b>LEI<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwwidth70\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54639283&amp;newsitemid=20261110192535&amp;lan=en-US&amp;anchor=www.amf-france.org&amp;index=6&amp;md5=4c9ebaff4b349bb10863b838457c9f21\">www.amf-france.org<\/a>) or on Innate Pharma\u2019s website (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54639283&amp;newsitemid=20261110192535&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=7&amp;md5=5f3c17431e95ee2bd0c2871f9d01bd24\">www.innate-pharma.com<\/a>), and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, is not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261110192535\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261110192535\/en\/<\/a><\/span><\/p>\n<p><b>St\u00e9phanie Cornen<br \/>\n<\/b><br \/>VP, Investor Relations &amp; Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:stephanie.cornen@innate-pharma.fr\">stephanie.cornen@innate-pharma.fr<\/a><\/p>\n<p><b>Investor Relations<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:investors@innate-pharma.fr\">investors@innate-pharma.fr<\/a><\/p>\n<p><b>Media<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:communication@innate-pharma.fr\">communication@innate-pharma.fr<\/a><\/p>\n<p><b>KEYWORDS:<\/b> France Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261110192535\/en\/1245155\/3\/INNATEvertnoirDS.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET \/ 4:00 PM GMT, in London, at the IET London, Savoy Place. Professor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (ENA) Symposium. The event will include a review of the Phase 1 study&#8217;s safety, pharmacokinetic and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019849","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET \/ 4:00 PM GMT, in London, at the IET London, Savoy Place. Professor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (ENA) Symposium. The event will include a review of the Phase 1 study&#8217;s safety, pharmacokinetic and &hellip; Continue reading &quot;Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T06:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026\",\"datePublished\":\"2026-11-11T06:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/\"},\"wordCount\":1054,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/\",\"name\":\"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-11T06:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 - Market Newsdesk","og_description":"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in person and virtually on Wednesday, November 18, 2026 at 11:00 AM ET \/ 4:00 PM GMT, in London, at the IET London, Savoy Place. Professor Yohann Loriot, M.D., Ph.D. (Gustave Roussy) will join company management to discuss Phase 1 clinical data from the IPH4502 dose-escalation study being presented at the 2026 EORTC-NCI-AACR (ENA) Symposium. The event will include a review of the Phase 1 study&#8217;s safety, pharmacokinetic and &hellip; Continue reading \"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-11T06:03:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026","datePublished":"2026-11-11T06:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/"},"wordCount":1054,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/","name":"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-11T06:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261110192535r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-host-in-person-and-virtual-event-on-iph4502-on-november-18-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019849"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019849\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}